Stock analysts at B. Riley started coverage on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a note issued to investors on Monday, MarketBeat reports. The brokerage set a “buy” rating and a $11.00 price target on the biopharmaceutical company’s stock. B. Riley’s price target indicates a potential upside of 102.58% from the company’s current price.

Several other equities research analysts also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Tetraphase Pharmaceuticals in a report on Tuesday, February 6th. BidaskClub downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 12th. Finally, ValuEngine downgraded Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $14.46.

Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) opened at $5.43 on Monday. The stock has a market capitalization of $265.71, a price-to-earnings ratio of -1.90 and a beta of 2.29. Tetraphase Pharmaceuticals has a 1-year low of $4.91 and a 1-year high of $9.93.

In related news, Director L Patrick Gage purchased 3,880 shares of the business’s stock in a transaction on Wednesday, November 29th. The shares were bought at an average price of $6.45 per share, for a total transaction of $25,026.00. Following the acquisition, the director now directly owns 38,880 shares in the company, valued at $250,776. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jacques Dumas sold 8,750 shares of the company’s stock in a transaction dated Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total value of $54,425.00. Following the sale, the insider now owns 8,750 shares in the company, valued at approximately $54,425. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of TTPH. SG Americas Securities LLC purchased a new stake in Tetraphase Pharmaceuticals during the 3rd quarter worth about $107,000. Brighton Jones LLC purchased a new stake in Tetraphase Pharmaceuticals during the 3rd quarter worth about $108,000. Voya Investment Management LLC increased its holdings in Tetraphase Pharmaceuticals by 17.8% during the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 3,104 shares during the period. Virtu KCG Holdings LLC purchased a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth about $147,000. Finally, Ameriprise Financial Inc. purchased a new stake in Tetraphase Pharmaceuticals during the 2nd quarter worth about $162,000. Institutional investors own 58.28% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Tetraphase Pharmaceuticals (TTPH) Coverage Initiated at B. Riley” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://theolympiareport.com/2018/02/14/tetraphase-pharmaceuticals-ttph-coverage-initiated-at-b-riley.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.